Sign inJoin waitlistJoin the waitlist

PL

Philip Lammers

Assistant Professor · University of Tennessee College of Medicine

Credentials: · · · · · ·

History

University of Tennessee College of Medicine
Present

Hematology and Medical Oncology
Vanderbilt University Medical Center
2010–2013
Internal Medicine
Barnes-Jewish Hospital
2006–2009
Indiana University School of Medicine
2002–2006

Research

Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium
Annals of Oncology · 2021 · 260 citations
Assessment of Treatment With Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients With Advanced Hepatocellular Carcinoma: Phase 3 CALGB 80802 Randomized Clinical Trial
JAMA Oncology · 2019 · 101 citations
Barriers to the Use of Trastuzumab for HER2+ Breast Cancer and the Potential Impact of Biosimilars: A Physician Survey in the United States and Emerging Markets
Pharmaceuticals · 2014 · First of 4 authors · Corresponding · 77 citations

LH
Leora Horn
5 papers
David Carbone
4 papers
Ali Khaki
3 papers
Babar Bashir
3 papers
Chinmay Jani
3 papers
DF
Daniel Flora
3 papers
Daniel Stover
3 papers
Elizabeth Wulff
3 papers
Gary Lyman
3 papers
Gayathri Nagaraj
3 papers
GW
Georgia Wiesner
3 papers
Iftikhar Kullo
3 papers

Grants

1/3) MMC, VICC, and TSU: Partners in Eliminating Cancer Disparities
National Cancer Institute · U54
PI · $5.2M · Meharry Medical College
2011–2021

Clinical trials

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Site PI · Recruiting · Phase 3
Stemline Therapeutics, Inc.
2024–2032
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
Site PI · Recruiting · Phase 3
SWOG Cancer Research Network
2023–2033
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
Site PI · Recruiting
Adela, Inc
2022–2027
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2020–2026